Download
43_s40272-022-00540-z.pdf 744,53KB
WeightNameValue
1000 Titel
  • Adverse Drug Reactions in Children: Comparison of Reports Collected in a Pharmacovigilance Project Versus Spontaneously Collected ADR Reports
1000 Autor/in
  1. Leitzen, Sarah |
  2. Dubrall, Diana |
  3. Toni, Irmgard |
  4. Stingl, Julia |
  5. Christ, Patrick |
  6. Köberle, Ursula |
  7. Schmid, Matthias |
  8. Neubert, Antje |
  9. Sachs, Bernhardt |
1000 Erscheinungsjahr 2022
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2022-11-12
1000 Erschienen in
1000 Quellenangabe
  • Ahead of print
1000 FRL-Sammlung
1000 Copyrightjahr
  • 2022
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s40272-022-00540-z |
1000 Ergänzendes Material
  • https://link.springer.com/article/10.1007/s40272-022-00540-z#Sec36 |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • BACKGROUND: Adverse drug reactions (ADRs) and medication errors in children may result from a lack of appropriate drugs, dosages, and pharmaceutical forms. In addition, children may respond differently to drugs than adults. Reporting of ADRs in the pediatric population is therefore of importance in order to increase the amount of safety data. However, different methodological approaches are used to collect ADRs. OBJECTIVE: The aim of the present study was to analyze whether there were differences in the ADRs collected in the KiDSafe project (845 ADR reports) compared with the spontaneous ADR reports sent to EudraVigilance (697 reports) in the same time period. The strengths and limitations of these two different approaches should be discussed. METHODS: The same inclusion criteria were applied for the systematically collected ADRs in the KiDSafe project and the spontaneous reports from EudraVigilance, and only reports of ADRs coded with hospitalization were considered. In both datasets, the number of reports (related to number of hospitals), their documentation quality (VigiGrade), causal relationship (World Health Organization-Uppsala Monitoring Centre [WHO-UMC] criteria), most frequently reported drugs and ADRs, demographical parameters of the patients, reported medical histories, and the seriousness of ADR reports were analyzed descriptively. The results of the two analyses were compared. RESULTS: There was considerable underreporting of ADRs via the spontaneous reports (0.4 reports per hospital; 697/1902) compared with 70.4 reports per hospital (845/12) in the systematically collected KiDSafe reports. Documentation quality assessment yielded similar results in both datasets. Among the 10 most frequently reported drugs, anticonvulsants such as levetiracetam (6.6%), valproic acid (5.6%), oxcarbazepine (3.6%), and lamotrigine (3.4%) were mainly reported in the KiDSafe reports, while in the EudraVigilance reports, mite allergen extract (4.4%) and allergens (3.6%) were preferentially reported. Seizures were the most frequently reported clinically specific ADRs in the KiDSafe reports, whereas anaphylactic reactions and urticaria were prominent in the spontaneous reports from EudraVigilance. Notably, the proportion of reports referring to medication errors and other medication safety related issues were more prominent in KiDSafe than in the spontaneous reports (27.8% vs. 12.6% and 46.0% vs. 29.0%, respectively). CONCLUSION: In general, reports from both data sources contributed to the identification of ADRs and dedicated issues related to drug therapy. However, these differed by nature and strength of the signal, likely due to the characteristics of the individual method. A combined approach could likely compensate for limitations inherent to the single approaches, but will most likely only be applied to dedicated pharmacovigilance topics or research objectives.
1000 Sacherschließung
lokal adverse drug reactions (ADRs)
lokal Pharmacovigilance
lokal EudraVigilance Database
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-1207-4168|https://orcid.org/0000-0002-8763-051X|https://orcid.org/0000-0002-0089-1494|https://orcid.org/0000-0002-1566-8156|https://orcid.org/0000-0003-3197-5639|https://orcid.org/0000-0001-8537-202X|https://orcid.org/0000-0002-0788-0317|https://orcid.org/0000-0001-6575-1452|https://orcid.org/0000-0001-8260-0891
1000 Label
1000 Förderer
  1. Projekt DEAL |
1000 Fördernummer
  1. -
1000 Förderprogramm
  1. Open Access funding
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Projekt DEAL |
    1000 Förderprogramm Open Access funding
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6438738.rdf
1000 Erstellt am 2022-12-14T13:59:37.850+0100
1000 Erstellt von 280
1000 beschreibt frl:6438738
1000 Bearbeitet von 25
1000 Zuletzt bearbeitet Tue Dec 20 09:44:42 CET 2022
1000 Objekt bearb. Tue Dec 20 09:44:42 CET 2022
1000 Vgl. frl:6438738
1000 Oai Id
  1. oai:frl.publisso.de:frl:6438738 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source